Prevalence of obese US adults could nearly double in percentage under new definition: Study

Researchers from Beth Israel Deaconess, Harvard and Yale applied the Lancet Commission's waist-based obesity criteria to NHANES data (n>14,000, representing 237.7 million U.S. adults, 2017–2023) and found 75.2% of adults met obesity criteria using waist measurements versus 40% when using BMI alone. The study — published in JAMA Network Open — notes nearly all adults aged 50+ would be classified as obese under the new definition, highlights limitations of BMI as a standalone tool, and urges age-specific thresholds and further research before broad adoption, which could affect healthcare policy, resource allocation and market demand for related treatments and services.

Analysis

Market structure: Reclassifying obesity to include waist-based metrics materially expands the addressable population (study implies ~75% vs 40%), which increases potential demand for weight-management drugs, diagnostics and virtual care. Clear near-term winners are large GLP‑1 manufacturers (Novo Nordisk, Eli Lilly) and diagnostic/laboratory players that bill for expanded screening (Hologic, Quest/LabCorp), while payers and lower-margin commercial weight programs (WW) face cost pressure. Pricing power shifts to incumbents with scale in drug manufacturing and specialty pharmacy distribution; smaller therapeutics or boutique programs risk margin compression.

Risk assessment: Tail risks include immediate payer pushback (coverage restrictions or step-therapy) and manufacturing bottlenecks for GLP‑1s; a 30–90 day window is plausible for initial payer guidance, while regulatory adoption could take 6–24 months. Hidden dependencies: increased prevalence on paper does not equal prescription uptake — clinician guidelines, age-specific thresholds and CPT/CMS billing codes are gating factors. Catalysts that would accelerate uptake: CMS coverage expansion, major insurer policy changes, or large pharma capacity increases; contrarily, new adverse-event data or supply caps would reverse momentum.

Trade implications: Over 3–12 months, the highest-conviction trades are long large-cap GLP‑1 makers and diagnostics, financed with defined-risk option structures to hedge policy risk. Relative opportunities include long LLY or NVO versus short WW or smaller tele-nutrition providers; expect elevated options IV around earnings and policy announcements. Entry should be staged: initial exposure ahead of 30–90 day payer signals, scale on confirmed coverage or supply announcements.

Contrarian angles: Consensus assumes broad conversion of prevalence to prescriptions — that is likely overstated. Historical parallels (e.g., broadened hypertension/diabetes criteria) show prevalence jumps often precede slow adoption into costly therapeutics; long-term prevention programs could reduce lifetime drug spend. The largest mispricing risk is overpaying for growth expectations in smaller weight‑management names that lack supply or formulary access.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Eli Lilly (LLY) over the next 30 days, add up to +2% on any CMS/major-insurer coverage signals within 90 days; set a tactical stop-loss at -12% and a 12–18 month target of +30–50% contingent on uptake.
• Open a 12-month call spread on Novo Nordisk (NVO) (buy 1.5–2% notional 12-month calls, sell a higher strike to finance) to capture upside from expanded addressable market while capping premium exposure; roll/trim if IV spikes >40% before policy announcements.
• Initiate a 1% long position in diagnostic/lab exposure via Hologic (HOLX) or Quest (DGX) (split allocation) to capture increased waist/DEXA/clinical screening volume; increase to 2–3% if CMS assigns new CPT/billing codes within 60–120 days.
• Implement a pair trade: long LLY (1.5%) / short WW International (WW) (1.0%) to express productized drug winners vs commercial diet programs; use equal-dollar sizing, tighten short if WW rallies >25% on headline noise.
• Monitor specific catalysts weekly for 90 days: CMS/Medicare guidance on obesity coverage, major insurer formulary updates, Lancet Commission policy adoption, and quarterly manufacturing capacity announcements from NVO/LLY — treat any positive CMS/insurer policy change as a signal to add 50–100% to GLP‑1 exposure.